Diseases & Longevity · File 13

Atrial fibrillation. The silent arrhythmia that multiplies stroke risk by 5.

Atrial fibrillation affects over 60 million adults worldwide and its prevalence will double in coming decades. It multiplies ischemic stroke risk by 5 and overall mortality by 2. A significant proportion is silent — only detected with prolonged ECG monitoring. That is the window where longevity medicine operates: early detection + addressing the underlying cardiometabolic cluster.

Why AF is the most underdetected arrhythmia in longevity

AF has a clinical characteristic that makes it one of the main event-generators in longevity: a significant proportion is silent or briefly paroxysmal, with no perceptible symptoms. The patient may have AF episodes lasting hours or days — enough to generate atrial thrombus — without knowing, until that thrombus embolizing to the CNS produces a cryptogenic stroke (no apparent cause).

Detection requires prolonged ECG monitoring — Holter 7-14 days, rhythm patches, or implantable monitoring in selected patients. Wearables (Apple Watch, Fitbit with ECG, Withings) have significantly expanded population detection capacity — the Apple Heart study 2019 (Perez et al., NEJM) showed feasibility of mass screening in asymptomatic adults. Detection changes management: identifies anticoagulation candidates per CHA2DS2-VASc.

Silent AF is the stroke that has not yet happened. Detecting it with prolonged monitoring directly changes individual prognosis.
People with AF · worldwide

The global weight, in numbers

AF burden is quantified in global cohorts (GBD, Framingham, Apple Heart) and national registries. These points sustain clinical priority.

  • Global prevalence

    60M+ adultos

    AF affects over 60 million adults globally (2019). Doubling is projected in coming decades due to population aging and cardiometabolic cluster increase.
    — GBD 2019; Chugh et al., Circulation 2014

  • Stroke risk

    ×5 isquémico

    AF multiplies ischemic stroke risk by 5 and represents ~20-30% of all strokes in older adults. AF strokes are typically more severe and have worse functional prognosis than atherothrombotic.
    — Chugh et al., Circulation 2014

  • Overall mortality

    ×2

    AF doubles overall mortality vs matched controls — independent effect combining stroke risk, heart failure, systemic thromboembolic events, and comorbidities.
    — Framingham; Chugh 2014

  • Wearable screening

    Apple Heart · n=419,297

    Apple Heart Study (Perez 2019 NEJM, n=419,297) demonstrated feasibility of mass screening with consumer wearables in asymptomatic adults — opening a new pathway for early population detection.
    — Perez et al., NEJM 2019

Chap. 03 · Comorbidity axis

Impact on quality of life and comorbidity

AF doesn't just increase stroke risk — it coexists with a comorbidity ecosystem that longevity medicine must address together.

  • Heart failure

    Bidireccional

    AF and HF are bidirectional: AF accelerates HF (tachycardiomyopathy, loss of atrial contraction, irregular rhythm) and HF induces atrial remodeling favoring AF. Managing them together is indispensable.
    — Wang et al., Circulation 2003

  • Cognitive decline

    ↑ riesgo demencia

    AF is associated with higher cognitive decline and dementia risk (vascular and mixed) — even without clinical stroke, due to silent microemboli and chronic decreased cardiac output.
    — Madhavan et al., Eur Heart J 2018

  • Sleep apnea (OSA)

    ~50% comorbilidad

    Up to 50% of AF patients have concomitant obstructive sleep apnea. Untreated OSA predicts post-ablation recurrence and rhythm control resistance — its treatment significantly improves outcomes.
    — Linz et al., Eur Heart J 2018

  • Cumulative burden

    Sintomática + asintomática

    Modern "AF burden" concept — percentage of time in AF — predicts outcomes better than classical category (paroxysmal vs persistent). That justifies prolonged screening and wearables.
    — Wong et al., JACC 2018

What we don't offer — and what we do

Wellness Care does not perform AF ablation nor manage acute arrhythmic events. Decision of rhythm control vs rate control, specific anticoagulation, cardioversion, and ablation belong to the cardiologist and electrophysiologist. What we do is what the fragmented system rarely integrates: early detection in asymptomatic high-risk patients, addressing the underlying cardiometabolic cluster, and managing comorbidities (OSA, sarcopenia, depression).

We evaluate patients with intermittent palpitations, family history of AF, cardiometabolic cluster, suspected OSA, or already diagnosed AF patients under cardiology management but with unaddressed comorbidities. Screening can include prolonged ECG monitoring (Holter 7-14 days), wearable validation (Apple Watch, Fitbit), and cluster evaluation: ApoB, hsCRP, metabolic profile, polysomnography when indicated.

Silent AF is the stroke that has not yet happened. Detecting it and addressing the underlying cluster is not optional — it is where cardiovascular longevity is decided.
How we measure it

How AF is evaluated
at Wellness Care

Detection + cardiometabolic cluster + comorbidities, under cardiology and electrophysiology coordination.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the AF conversation in longevity medicine — global epidemiology, wearable screening, AF burden, and comorbidities.

«La FA multiplica por 5 el riesgo de ictus isquémico y por 2 la mortalidad global — y una proporción significativa es silente, lo que exige monitorización prolongada.»
Circulation · 2014
Chugh et al., Circulation 2014
Epidemiología global FA
«El cribado masivo de FA con wearables consumer en adultos asintomáticos es factible y permite detección temprana de paroxismos clínicamente relevantes.»
NEJM · 2019
Perez et al., NEJM 2019
Apple Heart Study
«La FA y la apnea obstructiva del sueño coexisten en ~50% de los casos — el tratamiento de la OSA mejora significativamente la recurrencia y el control de ritmo.»
Eur Heart J · 2018
Linz et al., Eur Heart J 2018
FA + OSA + ritmo

Frequently asked questions about atrial fibrillation

The most recurrent questions about AF, prolonged monitoring and wearable detection, anticoagulation, and why longevity medicine complements the cardiologist.

01

How reliable are wearables (Apple Watch, Fitbit) for detecting AF?

Modern wearables with single-lead ECG (Apple Watch Series 4+, Fitbit Sense, Withings) have reasonable sensitivity and specificity for AF.

The Apple Heart Study showed irregular pulse notifications have a positive predictive value of ~84% for confirmed AF.

They do not replace clinical ECG, but are useful for:

· Population screening
· Triggers for formal monitoring in suspected patients

02

When is anticoagulation indicated in AF?

The CHA2DS2-VASc score estimates annual stroke risk in AF patients.

Anticoagulation indication:

· Score ≥2 in men → oral anticoagulation
· Score ≥3 in women → oral anticoagulation
· Score ≥1 in men → individualized evaluation

Options:

· Direct anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban
· Warfarin — in mechanical valves

Final decision, dose, and follow-up belong to the cardiologist, considering bleeding risk (HAS-BLED).

03

Is brief paroxysmal AF really dangerous?

Yes.

Modern evidence shows even brief paroxysms of AF can generate atrial thrombus and predict stroke.

The "AF burden" concept — percentage of total time in AF — predicts outcomes better than classical category (paroxysmal vs persistent).

That means paroxysms detected with prolonged monitoring or wearables require formal clinical evaluation, even if the patient is asymptomatic between episodes.

04

Does sleep apnea really affect AF?

Yes, significantly.

Up to 50% of AF patients have concomitant obstructive sleep apnea.

Untreated OSA predicts:

· Post-ablation recurrence
· Worse rhythm control
· Higher AF burden

CPAP treatment (continuous positive pressure):

· Significantly improves rhythm control
· Reduces post-ablation recurrence

Studying sleep in every AF patient is priority.

05

When should I consult for suspected AF?

A valuation is worthwhile if you have:

· Intermittent palpitations
· Irregular pulse episodes detected by wearable
· Family history of AF
· Unexplained exertional dyspnea
· Previous cryptogenic stroke
· Cardiometabolic cluster (HTN + obesity + T2D)
· Suspected OSA

If you already have diagnosed AF under cardiology management, the longevity assessment complements management by addressing systemic comorbidities the cardiologist does not always treat.

The stroke that has not yet happened

Silent AF is the stroke that has not yet happened. Detecting it with prolonged monitoring directly changes prognosis.

Screening with wearables + prolonged monitoring when suspected, evaluation of cardiometabolic cluster and sleep apnea, coordination with cardiology — that is what a serious longevity clinic does in AF.

Palpitations, known AF, or cryptogenic stroke?

Book a comprehensive cardiovascular assessment

We evaluate cardiovascular profile (ECG, prolonged monitoring when indicated), inflammatory and metabolic profile, CHA2DS2-VASc score, HAS-BLED bleeding risk, cardiometabolic cluster comorbidities. Does not replace the cardiologist or electrophysiologist — it complements them.

Book cardiovascular assessment